The combination of diagnostics and therapeutics into a single "theragnostic" agent is a key breakthrough. This approach allows for better patient stratification and offers new hope for cancers like pancreatic ductal adenocarcinoma (PDAC), which have dismal survival rates.
Unlike cell-line derived (CDX) models, PDX models are grown directly from patient samples without a culture phase. This preserves the original tumor's heterogeneity, leading to more clinically relevant and predictive data in preclinical radiopharmaceutical studies.
There is no inherent conflict between speed and quality. High-quality studies prevent costly setbacks and generate reliable data, ultimately accelerating research programs. A low-quality study is what truly delays timelines by producing unusable or misleading results.
The most effective CRO partnerships transcend a simple client-vendor dynamic. Success hinges on viewing the CRO as an integrated part of the research team, fostering close collaboration in study design and maintaining open, continuous communication.